Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial

Bibliography

• PETERSEN U, BREMM K-D, DALHOFF A et al.: Synthesisand in vitro activity of Bay 12–8039, a new 8 methoxy-quinolone. Abstracts of the 36th ICAAC. New Orleans (1996) F1:100.
   Google Scholar
• DALHOFF A, PETERSEN U, ENDERMANN R: In vitro activ-ity of Bay 12-8039, a new 8 methoxy-quinolone. Che-motherapy (1996) 42:410–425.
   Google Scholar
• ••First publication to describe activity against a wide range ofpathogens.
   Google Scholar
• MARTEL AM, LEESON PA, CASTANER J: Bay-12-8039.Drugs of the Future (1997) 22:109–113
   Google Scholar
• WOODCOCK JM, ANDREWS JM, BOSWELL FJ, BRENWALDNP, WISE R: In vitro activity of Bay 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. (1997) 41:101–106.
   PubMed Web of Science ®Google Scholar
• ALDRIDGE KE, ASHCRAFT D: Comparison of the in vitroactivities of Bay 12-8039, a new quinolone and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. (1997) 41:709–711.
   PubMed Web of Science ®Google Scholar
• BRUEGGEMANN A, KUGLER KC, DOERNG V: In vitro ac-tivity of BAY 12-8039, a novel 8-methoxy-quinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus in fluenzae and Morexella catarrhalis. Antimicrob. Agents Chemo-ther. (1997) 41:1594–1597.
   PubMed Web of Science ®Google Scholar
• ••Describes in vitro activity of moxifloxacin against the threeprimary bacterial pathogens in the chest.
   Google Scholar
• GOLDSTEIN EJC, CITRON DM, HUDSPETH M, GERARDOSH, MERRIAM CV: In vitro activity of Bay 12–8039, a new 8 methoxy-quinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and ani-mal bite wound skin and soft tissue infections in hu-m an s . Antimicrob. Agents Chemother. (1 9 9 7) 41:1522–1527.
   Google Scholar
• FASS RJ: In vitro activity of Bay 12-8039, a new 8methoxy-quinolone. Antimicrob. Agents Chemother. (1997) 41:1818–1824.
   PubMed Web of Science ®Google Scholar
• MACGOWAN AP, BOWKER KE, HOLT HA, WOOTON M, REEVES DS: Bay 12-8039, a new 8-methoxy-quinolone: comparative in vitro activity with nine other antimi-crobials against anaerobic bacteria. J. Antimicrob. Che-mother. (1997) 40:503–509.
   PubMed Web of Science ®Google Scholar
• BAUERNFEIND A: Comparison of the antibacterial ac-tivities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. (1997) 40:639–651.
   PubMed Web of Science ®Google Scholar
• ••Large data set on comparative activity of moxifloxacin andseveral other new quinolones.
   Google Scholar
• KLUGMAN KP, CAPPER T: Concentration-dependentkilling of antibiotic resistant pneumococci by the methoxyquinolone moxifloxacin. J. Antimicrob. Che-mother. (1997) 40:797–802.
   PubMed Web of Science ®Google Scholar
• •Describes the bactericidal effect of moxifloxacin against pneumococci.
   Google Scholar
• EDLUND C, SABOUR I S, NORD CE: Comparative in vitroactivity of Bay 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. (1998) 17:193–195.
   PubMed Web of Science ®Google Scholar
• JI B, LOUNIS N, MASLO C, TRUFFOT-PERNOT C, BANNA-FOUS P, GROSSET J: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacte-rium tuberculosis. Antimicrob. Agents Chemother. (199) 42:2066-2069.
   Google Scholar
• GEORGOPOULOS A, BUXBAUM A, GRANINER W: Activityof Bay 12–8039 against 1154 clinical isolates of Strepto-coccus pneumoniae. Abstracts of the 36th ICAAC. New Or-leans (1996) F4:100.
   Google Scholar
• FELMINGHAM D, ROBBINS MJ, KEAKEY A et al.: In vitroactivity of Bay 12–8039 against bacterial respiratory tract pathogens, mycoplasmas and obligate anaerobic bacteria. Abstracts of the 36th ICAAC. New Orleans (1996) F8:101.
   Google Scholar
• THOMSON KS, BACKES SS, SANDERS CC: Susceptibility to Bay 12–8039 of pneumococci and staphylococci with varying levels of ciprofloxacin resistance. Ab-stracts of the 36th ICAAC. New Orleans (1996) F16:102.
   Google Scholar
• HOOGKAMP-KORSTANJE JAA: Activity of Bay 12–8039 against Gram-positive cocci. J. Clin. Microbic)]. Infect. (1997) 3 (Suppl. 2):P1153, 284.
   Google Scholar
• FELMINGHAM D, ROBBINS MJ, LEAKEY A et al: In vitroactivity of Bay 12–8039. J. Clin. Microbic)]. Infect. (1997) 3 (Suppl. 2):P1156–285.
   Google Scholar
• ALCALA L, GARCIA-GARROTE F, CERENADO E, BOUZA E.In vitro activity of the novel quinolone Bay 12–8039 against Gram-positive isolates. Abstracts of the 37th ICAAC. Toronto (1997) F128:168.
   Google Scholar
• REINERT RR, DALHOFF A, SCHLAEGER JJ, LEMPERLE M,LUTTICKEN R: In vitro activity of Bay 12–8039, a new 8-methoxy-quinolone against S. pneumoniae. Abstracts of the 37th ICAAC. Toronto (1997) F129:168.
   Google Scholar
• KAYSER FH, SANTANAM P, HUF E: Susceptibilities of in-vasive pneumococcal strains against the methoxy-quinolone Bay 12–8039 compared to other quinolones. Abstracts of the 37th ICAAC. Toronto (1997) F130:168.
   Google Scholar
• BLONDEAU JM, LASKOWSKI R, VAUGHAN D: In vitro ac-tivity of Bay 12–8039, a novel fluoroquinolone antimi-crobial agent. Abstracts of the 37th ICAAC. Toronto (1997) F155:172.
   Google Scholar
• GEORGOPOULOS A, MOSER C, BUXBAUM A, STRASCHIL U, GRANINGER W: Antipneumococcal activity of moxi-floxacin and trovafloxacin in comparison to older qui-nolones. Anti-infect. Drugs Chemother. (1998) 16\(Suppl. 1):T125, 67.
   Google Scholar
• FOCHT J, KLUSNER K: In vitro activity of moxifloxacin compared with other fluoroquinolones against bacte-rial strains from upper and lower respiratory tract in-fections in general practice. Anti-infect. Drugs Chemother. (1998) 16(Suppl.):T161, 76.
   Google Scholar
• TARASI A, CAPONE A, TARASI D, CASSONE M, VENDITI I: Comparative in vitro activity of Bay 12-8-39, penicillin, ceftriaxone, trimethoprim-sulphamethoxazole, ciprofloxacin against pneumococci isolated from meningitis. Abstracts of the 38th ICAAC. San Diego (1998) E203:228.
   Google Scholar
• MALATHUM K, SINGH KV, MURRAY BE: In vitro activity of Bay 12–8039 against Gram-positive bacteria. Ab-stracts of the 38th ICAAC. San Diego (1998) E204:228.
   Google Scholar
• HERRINGTON JA FEDERICI JA, PAINTER BG, REMY JM, BARBIERO ML, THURBERG BE: In vitro activity of Bay 12–8039, a new quinolone. Abstracts of the 36th ICAAC. New Orleans (1996) F4:100.
   Google Scholar
• VISALLI MA, JACOBS MR, APPELBAUM PC: Antipneumo-corral activity of Bay 12–8039, a new quinolone com-pared to 3 others quinolones and 5 13 lactams. Abstracts of the 36th ICAAC. New Orleans (1996) F6:101.
   Google Scholar
• SOULI M, WENNERSTEN CB, ELIOPOULOS GM: In vitro activity of Bay 12–8039, a novel methoxyquinolone against species representative of respiratory tract pathogens. Abstracts of the 37th ICAAC. Toronto (1997) F126:167.
   Google Scholar
• WEISS K, LAVERDIERE M, RESTIERI C: Comparative aci-tivity of new quinolones against 452 clinical isolates of Streptococcus pneumoniae. Abstracts of the 37th ICAAC. Toronto (1997) F131:168.
   Google Scholar
• ROBSON HG, TREMBLAY J-F, LOO VG, LAVALL EEJ, MCALEAR D: Comparative in vitro activity of tro-vafloxacin, Bay 12–8039, and clinafloxacin against penicillin intermediate and resistant Streptococcus pneumoniae. Abstracts of the 37th ICAAC. Toronto (1997) F135:169.
   Google Scholar
• MARCHESE A, DEBBIA EA, SCHITO GC: Comparative ac-tivity of Bay 12–8039 and other fluoroquinolones on clinical Streptococcus pneumoniae strains. Anti-infect. Drugs Chemother. (1998) 16\(Suppl. 1):T157, 75.
   Google Scholar
• VERBIST L, VERHAEGEN J: In vitro activity of moxifloxa-cin (Bay 12-8039) against Gram-positive clinical iso-lates. Abstracts of the 8th International Congress of Infectious Diseases. Boston (1998) 13.015: 23.
   Google Scholar
• LOZA E, MOROSINI MI, ALMARAZ F, NEGRI MC, BAQUERO F: Comparative in vitro activity of moxi-floxacin against respiratory tract pathogens. Abstracts of the 38th ICAAC. San Diego (1998) E206:229.
   Google Scholar
• KITZIS MD, GOLDSTEIN FW, MIEGI M, ACAR J: In vitro ac-tivity of Bay 12–8039 against multiple-resistant Staphy-lococcus aureus, Streptococcus pneumoniae and Enterococcus faecalis. Abstracts of the 36th ICAAC. New Orleans (1996) F12:102.
   Google Scholar
• PIDDOCK LJV, JIN Y-F: Activity and accumulation of Bay 12–80398. Abstracts of the 37th ICAAC. Toronto (1997) F127:167.
   Google Scholar
• DOUCET-POPULAIRE F, PANGON B, DOERMANN HP, GHNASSIA JC: In vitro activity of activity of a new fluoroquinolone Bay 12–8039 in comparision with ciprofloxacin and macrolides against Bordetella per-tusis. Abstracts of the 37th ICAAC. Toronto (1997) F145:170.
   Google Scholar
• HOPPE JE: In vitro activities of Bay 12–8039 and cipro-floxacin against Bordetella pertusis and Bordetella parapertusis. Abstracts of the 37th ICAAC. Toronto (1997) F146:170.
   Google Scholar
• HOPPE JE: In vitro activities of grepafloxacin, moxi-floxacin, ciprofloxacin and clarithromycin against Bordetella pertussis and Bordetella parapertusis. Ab-stracts of the 38th ICAAC. San Diego (1998) E212b:231.
   Google Scholar
• RUCKDESCHEL G, LOB S: In vitro activity of a new 8 methoxy-quinolone Bay 12–8039, against Legionella spp in comparison to ciprofloxacin, erythromycin and rifampicin. Abstracts of the 36th ICAAC. New Orleans (1996) F7:101.
   Google Scholar
• RENAUDIN H, BEBEAR CM, BOUDJADIA A: In vitro activ-ity of Bay 12–8039, a new fluoroquinolone against mycoplasmas. Abstracts of the 36th ICAAC. New Orleans (1996) F9:101.
   Google Scholar
• KENNY G, CARTWRIGHT FD: Susceptibilities of human mycoplasmas to Bay 12–8039. Abstracts of the 37th ICAAC. Toronto (1997) F143:170.
   Google Scholar
• ROBLIN PM, HAMMERSCHLAG MR: Activity of a new qui-nolone, Bay 12–8039, against Clamydia pneumoniae in vitro. Abstracts of the 36th ICAAC. New Orleans (1996) F11:101.
   Google Scholar
• DONATI M, RUMPIANESI F, PAVAN G, SAMBRI V, CEVENNI R: In vitro activity of Bay 12–8039 against Cla-mydia. Abstracts of the 37th ICAAC. Toronto (1997) F142:171.
   Google Scholar
• GROSS WM, VADNEY FS, LADUTKOL, BONATO DA, CAMPBELL S: In vitro activity of Bay 12–8039, a new 8-methoxy-quinolone against Mycobacteria. Abstracts of the 37th ICAAC. Toronto (1997) F144:170.
   Google Scholar
• SCHMITZ F-J, HOFMANN B, SCHEORING S et al.: Correla-tion of MIC values of ciprofloxacin, ofloxacin, levo-floxacin, sparfloxacin and Bay 12–8039 with mutations within grl A, grl B, gyr A, gyr B and nor A in 116 unre-lated clinical isolates of Staphylococcus aureus. Anti-infect. Drugs Chemother. (1998) 16\(Suppl. 1):T159, 75.
   Google Scholar
• BAUERNFEIND A, JUNEWORTH R: In vitro activity of the novel quinolone Bay 12–8039 in comparison with ciprofloxacin. Abstracts of the 36th ICAAC. New Orleans (1996) F3:100.
   Google Scholar
• JONES ME, KLOOTWIJK M, VERHOEFF J, SCHMITZ F-J: Comparative activity of Bay 12–8039 versus other qui-nolone and non-quinolone antibiotics against unre-lated clinical isolates of methicillin resistant and susceptible Staphylococcus aureus. Abstracts of the 38th ICAAC. San Diego (1998) F212:230.
   Google Scholar
• SANTANAM P, HUF E, KAYSER FH: Activity of Bay 12–8039 and further fluoroquinolones against speciated staphylococci and potential of staphylococci to de-velop resistance. Abstracts of the 38th ICAAC. San Diego (1998) E197:226.
   Google Scholar
• DEBBIA EA, MARCHESE A, SCHITO GC: Acitivity of Bay 12–8039 against well characterised antibiotic resistant S. pyogenes. Abstracts of the 37th ICAAC. Toronto (1997) F132:168.
   Google Scholar
• MARCHESE A, BACCA D, BALISTRERI G, MUSOLINO B, SCHITO GL: Activity of moxifloxacin (Bay 12–8039) against erythromycin resistant Streptococcus pyo-genes. Anti-infect Drugs Chemother. 16 (Suppl. 1):T158, 75.
   Google Scholar
• ESPOSITO S, NOVIELLO S, IANNIELLO F: In vitro activity of moxifloxacin compared to other quinolones against different erythromycin resistant phenotypes of Group A beta-haemolytic streptococci. Abstracts of the 38th ICAAC. San Diego (1998) E199:227.
   Google Scholar
• STRUWIG MIC, BOTHA PL, CHALKLEY LJ: Investigation of the antibacterial activity of Bay 12–8039 against South African isolates of Enterococci. Abstracts of the 37th ICAAC. Toronto (1997) F138:169.
   Google Scholar
• MANZANARES MAA, ZUFIAURRE MNG, CRIADO SM, BEL-LIDO JLM, GARCIA- RODRIGUEZ JA: In vitro activity of fluorinated quinolones against Enterococcus faecalis. Abstracts of the 8th International Congress on Infectious Dis-eases (1998) 12.037: 20.
   Google Scholar
• HOOGKAMP-KORSTANJE JAA: Activity of Bay 12–8039 against aerobic and anaeroboic Gram-positive rods. J. Microbiol. Infect. (1997) 3 (Suppl. 2):P1153, 284.
   Google Scholar
• VALDEZATE S, MARTIN-DAVILA P, VINDEL A, BAQUERO F, SANCHEZ B, CANTON R: New fluoroquinolones: in vi-tro comparative activities against Stenotrophomonas maltophilia. Abstracts of the 38th ICAAC. San Diego (1998) E209:230.
   Google Scholar
• LOPEZ-MERINO A, CONTRERAS-RODRIGUEZ A, ORRANTIA-GRADIN R, HERMANDEZ-OLIVA GM, GUTIERREZ-RUBIO AT: Susceptibility from Brucella spp strains to moxifloxacin, ciprofloxacin and other current antimicrobials used in the treatment of human brucellosis. Abstracts of the 8th International Congress on Infectious Diseases (1998) 12.023: 17.
   Google Scholar
• BETRU C, GOMEZ M, PALAU ML, SANCHZ A, PICAZO JJ: In vitro activity of a new fluroquinolone, Bay 12–8039 against Bacteroides fragilis group. Abstracts of the 38th ICAAC. San Diego (1998) E209:230.
   Google Scholar
• FEDERICI JA, HERRINGTON JA, PAINTER BG, REMY JM, THURBERG BE: The bactericidal activity of Bay 12–8039 against respiratory tract pathogens. Abstracts of the 36th ICAAC. New Orleans (1996) F13:102.
   Google Scholar
• HERRINGTON JA, REMY JM, FEDERICI JA, HUGUENEL ED:The bactericidal activity of Bay 12–8039 against respi-ratory pathogens at clinically achievable serum con-centrations. Abstracts of the 37th ICAAC. Toronto (1997) F125:167.
   Google Scholar
• VISALLI M, JACOBS M, APPELBAUM P: Antipneumococ-cal activity of Bay 12–8039 compared to other drugs by time-kill. Abstracts of the 37th ICAAC. Toronto (1997) F133:168.
   Google Scholar
• DURHAM EJ, AMYES SGB, DALHOFF A, THOMSON CJ: Invitro activity of Bay 12–8039 against Staphylococcus aureus. Abstracts of the 37th ICAAC. Toronto (1997) F139:169.
   Google Scholar
• BOSWELL F, ANDREWS JM, WISE R: Pharmacodynamic properties of Bay 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and post antibiotic effect. Antimi-crob. Agents Chemother. (1997) 41:1377–1379.
   PubMed Web of Science ®Google Scholar
• ••First published manuscript on PAE and concentration-related killing.
   Google Scholar
• ROBINSTEIN E, DIAMANTSTEIN L, GRUZMANN G, SEGEVS, BARZILAI A: The effect of albumin, globulin, pus, dead bcteria and anaerobic conbditions on the anti-bacterial activities and PAE of Bay 12–8039, tro-vafloxain and ciprofloxacin. Abstracts of the 38th ICAAC. San Diego (1998) D436:140.
   Google Scholar
• DAVIDSON RJ, FULER J, LOW DE: Pharmacodynamic properties of moxifloxacin, levofloxacin and clarithromycin in S. pneumonia and H. influenzae. Ab-stracts of the 38th ICAAC. San Diego (1998) E200:227.
   Google Scholar
• MAGGIOLO F, CAPRA R, BARTOLI A, SILANOS MA, TEL-LARINI M, SUTTER F: Sub inhibitory concentrations of Bay 12–8039: pharmacodynamic effect in vitro. Ab-stracts of the 37th ICAAC. Toronto (1997) F147:171.
   Google Scholar
• AL-NAWAS B, SHAH PM: Intracellular activity of cipro-floxacin and Bay 12–8039.1 Clin. Microbiol. Infect. (1997) 3 (Suppl. 2):P1152, 284.
   Google Scholar
• ADAM D: Influence of Bay 12–8039 on phagocytosis, burst - and killing - (PBK) activities of human granulo-cytes. Abstracts of the 37th ICAAC. Toronto (1997) F149:171.
   Google Scholar
• GEMMELL CG, BLAIR NJ, PIDDOCK LJV: Influence of Bay12-8039 on the intracellular survival of strains of Sal-monella typhimurium of different susceptibilities. Ab-stracts of the 8th International Congress of Infectious Diseases (1998) 82.026: 233.
   Google Scholar
• PONG A, THOMSON KS, MOLAND ES, CHARTLAND SA, SANDERS CC: Activity of Bay 12–8039 against staphylo-coccal and pneumococcal mutants with diminished susceptibility or resistance to ciprofloxacin. Abstracts of the 37th ICAAC. Toronto (1997) C85:61.
   Google Scholar
• DALHOFF A: Disassociated resistance among fluoro-quinolones. Anti-infect. Drugs Chemother. (1998) 16\(Suppl. 1):T160, 75.
   Google Scholar
• DALHOFF A, HEIDTMANN M, OBERTEGGER S, HESSE D:Lack of in vivo emergence of resistance against Bay 12–8039 in Staphylococcus aureus and Streptococcuspneumoniae. Abstracts of the 8th International Congress on Infectious Diseases. Boston (1998) 47.003: 124.
   Google Scholar
• TANKOVIC J, BECHOULL R, LECLERCQ L, SOUSSY CJ: In vitro activity of Bay 12–8039 against fluoroquinolone-resistant Gram-negative bacilli and Enterococcus fae-calis. Abstracts of the 37th ICAAC. Toronto (1997) F136:169.
   Google Scholar
• CHAUVEL M, COURVALIN P: Comparative activity of Bay 12–8039 against isogenic quinolone susceptible and re-sistant Streptococcus pneumoniae, Staphylococcus aureus and Enterococcus faecalis. Abstract of the 38th ICAAC. San Diego (1998) C47:82.
   Google Scholar
• TARASI A, MONACO M, TARASI D, CASSONE M, CAPONE A, VENDITTI M: Activity of Bay 12–8039 in combination with vancomycin or teicoplanin against Staphylococ-cus aureus isolated from device associated infection unresponsive to glycopeptide therapy. Anti-infect. Drug Chemother. (1998) 16\(Suppl. 1):T151, 73.
   Google Scholar
• MAGGIOLO F, CAPRA R, SILANOS MA, BOTTURA P, PRAVETTONI G, SUTER F: Bactericidal effect of Bay 12–8039 associated with other antibacterials on methicil-lin resistant Staphylococcus aureus (MRSA). Anti-infect. Drug Chemother. (1998) 16\(Suppl. 1):T162, 76.
   Google Scholar
• MAGGIOLO F, CAPRA R, BOTTURA P, MORONI M, PRAVETTONI G, SUTER F: In viro bactericidal effect of moxifloxacin alone and in combination against van-comycin resistant Enterococci. Abstracts of the 38th ICAAC. San Diego (1998) E201:227.
   Google Scholar
• VESGA 0, CONKLIN R, STAMSTAD T, CRAIG WA: Pharma-codynamic activity of Bay 12–8039 in animal infection models. Abstracts of the 36th ICAAC. New Orleans (1996) F22:103.
   Google Scholar
• ••Pharmacodynamics of moxifloxacin in one of the best-established animal pharmacodynamic models.
   Google Scholar
• DALHOFF A: Antibacterial efficacy of fluctuating con-centrations of Bay 12–8039 simulating human serum concentrations. Abstracts of the 36th ICAAC. New Orleans (1996) F26:104.
   Google Scholar
• BOWKER KE, WOOTTON M, HOLT HA, REEVES DS, MACGOWAN AP: Bactericidal activity of Bay 12–8039 against Streptococcus pneumoniae explored using an in vitro continuous bactericidal culture model. Ab-stracts of the 37th ICAAC. Toronto (1997) F134:169.
   Google Scholar
• WIEDEMANN B: Pharmacodynamic activity of moxi-floxacin in an in vitro model against Gram-positive and Gram-negative pathogens. Abstracts of the 8th Inter-national Congress on Infectious Diseases. Boston (1998) 12.001: 13.
   Google Scholar
• LISTER PD, SANDERS CC: Pharmacodynamics of moxi-floxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Abstracts of the 38th ICAAC. San Diego (1998) A21:7.
   Google Scholar
• ZINNER S, GILBERT D, SIMMONS K, SARLAK E: Moxi-floxacin activity against S. pneumoniae in an in vitro dynamic model. Abstracts of the 38th ICAAC. San Diego (1998) A26:8.
   Google Scholar
• WOOTTON M, BOWKER KE, HOLT HA, MACGOWAN AP: Bactericidal activity of moxifloxacin against Staphylo-coccus aureus and Group A streptococci exploredusing a pharmacodynamic model of infection. Abstrcts of the 38th ICAAC. San Diego (1998) A32:10.
   Google Scholar
• BOWKER KE, WOOTTON M, HOLT HA, MACGOWAN AP: In vitro activity of moxifloxacin against Haemophilus influenzae and Morexella catarrhalis investigated us-ing a pharmacodynamic model of infection. Abstracts of the 38th ICAAC. San Diego (1998) E207:229.
   Google Scholar
• ZHANEL G, LAING N, KARLOWSKY J, HOBAN D: In vitro characterisation of moxifloxacin and comparitor qui-nolones induced killing of multiple drug resistant Streptococcus pneumoniae by simulating clinically achievable area-under-the-curve. Abstracts of the 38th ICAAC. San Diego (1998) A24:8.
   Google Scholar
• NICHTERLEIN T, KRETSCHMAR M, HOF H: Bay 12–8039 a new quinolone derivative is superior to standard therapeutics in murine salmonellosis and listeriosis. Abstracts of the 36th ICAAC. New Orleans (1996) F14:102.
   Google Scholar
• JACOBS E, DALHOFF A, BRUNNER H: Efficacy of Bay 12–8039 in Mycoplasma pneumoniae infected guinea pigs. Abstracts of the 36th ICAAC. New Orleans (1996) F17:102.
   Google Scholar
• WATERBURY K, WANG JJ, BARBIERO N, FEDERICI J, OH-LIN AC, HUGENEL ED: Efficacy of Bay 12–8039, a potent new quinolone in mouse models of typical and atypi-cal respiratory infection. Abstracts of the 36th ICAAC. New Orleans (1996) F18:103.
   Google Scholar
• ROUSE MS, PIPER KE, PATEL R, WILSON WR, STECKEL-BERG JM: In vitro and in vivo activity of Bay 12–8039 or trovafloxacin against penicillin resistant Streptococ-cus pneumoniae experimental pneumonia in immu-nocompetent mice. Abstracts of the 36th ICAAC. New Orleans (1996) B45:29.
   Google Scholar
• ROUSE MS, PIPER KE, PATEL R, WILSON WR, STECKEL-BERG JM: In vitro and in vivo activity of ciprofloxacin, levofloxacin, sparfloxacin or Bay 12–8039 against penicillin resistant Streptococcus pneumoniae. Ab-stracts of the 37th ICAAC. Toronto (1997) B3:26.
   Google Scholar
• SCMIDT H, DALHOFF A, STUERTZ K, TROSTDORF F, KOHLSDORFER C, NAU R. Cerebro spinal fluid (CSF) fil-tration for experimental pneumococcal meningitis. Abstracts of the 37th ICAAC. Toronto (1997) B-79:41.
   Google Scholar
• SCHMIDT H, DALHOFF A, STUERTZ K et al.: Moxifloxacinin the therapy of experimental pneumococcal menin-gitis. Antimicrob. Agents Chemother. (1998) 42:1397–1401.
   PubMed Web of Science ®Google Scholar
• OSTERGAARD C, KLITMOLLER-SORENSEN T, KNUDSENJD, FRIDMODT-MOLLER N: Evaluation of moxifloxacin, a new 8 methoxy-quinolone, for treatment of meningi-tis caused by a penicillin resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. (1998) 42:1706–1712.
   PubMed Web of Science ®Google Scholar
• ENTENZA J-M, GIDDEY M, GLAUSER MP, MOREILLON P: Efficacy of the novel quinolone Bay 12–8039 in the treatment of experimental endocarditis due to cipro-floxacin susceptible and resistant MRSA. Abstracts of the 38th ICAAC. San Diego (1998) B78:67.
   Google Scholar
• MIYAZAKI E, CHAISSON RE, BISHARI WR: In vivo activity of Bay 12–8039, a new 8 methoxy quinolone in a mousemodel of tuberculosis. Abstracts of the 38th ICAAC. San Diego (1998) E210:230.
   Google Scholar
• STUERTZ K, SCHMIDT H, TROSTDORF F, EIFFERT H, MADER M, NAU R: Reduced lipo teichoic and teichoic acid release during treatment of experimental Strepto-coccus pneumoniae meningitis with non bacteriolytic antibiotics moxifloxacin, trovafloxacin, rifabutin and quinupristin-dalfopristin. Abstracts of the 38th ICAAC. San Diego (1998) B2:45.
   Google Scholar
• STASS HM, DALHOFF A: Determination of Bay 12-8039,a new methoxy quinolone in body fluids by HPLC with fluorescence detection using on column focusing. J. Chromotogr. (1997) 702:163–174.
   Web of Science ®Google Scholar
• •Description of HPLC assay method.
   Google Scholar
• SUNDERLAND J, MCMULLIN CM, WHITE LO, MACGOWANAP, REEVES DS: An isocratic high performance liquid chromatographyl assay (HPLC) for the new 8-methoxy-quinolone: comparison of the pharmacoki-netics in different mammalian species. Abstracts of the 36th ICAAC. New Orleans (1996) F20:103.
   Google Scholar
• SIEFERT HIM, BUHNER K, DOMDEY-BETTE A, GOLLER G, KOHLSDORFER C, STEINKE W: Bay 12–8039, a new 8 methoxy-quinolone: pharmacokinetics in rats and monkeys. Abstracts of the 36th ICAAC. New Orleans (1996) F19:103.
   Google Scholar
• SIEFERT HIM, HENNINGER K, HUCKE F, KOHLSDORFERC, STASS H: Bay 12–8039, a new methoxy-quinolone: as-pects of absorption in experimental animals and man. Abstracts of the 37th ICAAC. Toronto (1997) F151:171.
   Google Scholar
• RUBINSTEIN E, MUSAFIJA A, STEHLMAN Y, BARZILAI A, SEGEV S: The transepithelial intestinal elimination of Bay 12–8039 in rabbits. Abstracts of the 38th ICAAC. San Diego (1998) A122:39.
   Google Scholar
• KERN A, KANHAI W, FROHDE R, KARL W, BADER A: Bay 12–8039, a new 8 methoxy-quinolone: metabolism in rat, monkey and man. Abstracts of the 37th ICAAC. To-ronto (1997) F23:103.
   Google Scholar
• STASS H, DALHOFF A, KUBITZA D, SCHUHLY U: Pharma-cokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8 methoxy-quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. (1998) 42:2060–2065.
   PubMed Web of Science ®Google Scholar
• ••Only data available to date on pharmacokinetics ofmoxifloxacin.
   Google Scholar
• STASS HH, KUBITZA D, SCHUHLY U: Bay 12–8039 a new 8 methoxy-quinolone: pharmacokinetic safety and tol-erability of single ascending intravenous doses in healthy male volunteers. Abstracts of the 37th ICAAC. To-ronto (1997) F1523:172.
   Google Scholar
• STASS H, DALHOFF A, FUBITZA D: Bay 12-8039, study on the food effect after oral administration of 200 mg SD to healthy volunteers. J. Clin. Microbic)]. Infect. (1997) 3 (Suppl 2):P385, 86.
   Google Scholar
• STASS HH, DIETRICH H, SACHSE R: Influence of a four times dosing of 500 mg probenecid on kinetics of Bay 12–8039 after administration of a single 400 mg dose in healthy male volunteers. Abstracts of the 37th ICAAC. To-ronto (1997) F154:172.
   Google Scholar
• STASS H, KUBITZA D: Study to evaluate the interaction between moxifloxacin and iron supplements. Anti-infect. Drugs Chemother. 16\(Suppl. 1):T154, 74.
   Google Scholar
• STASS H, KUBITZA D: Study to assess the interaction be-tween moxifloxacin and dairy products in healthy vol-unteers. Anti-infect. Drugs Chemother. 16(Suppl.):T156, 74.
   Google Scholar
• SULLIVAN JT, LETTIERI J, HOEAN CM, HELLER AM: Age and gender effects on pharmacokinetics of Bay 12-8039. Abstracts of the American Society for Clinical Phar-macology & Therapeutics. New York (1997) PI–46:148.
   Google Scholar
• STASS H, HALABI A, DELESEN H: No dose adjustment needed for patients with renal impairment receiving oral Bay 12–8039. Abstracts of the 38th ICAAC. San Diego (1998) A14:5.
   Google Scholar
• KUBITZA D, STASS HM, WINGENDER W, KUHLMANN J: Bay 12–8039, a new 8 methoxy-quinolone, safety, toler-ability and steady state pharmacokinetics in healthy male volunteers. Abstracts of the 36th ICAAC. New Or-leans (1996) F25:104.
   Google Scholar
• SULLIVAN JT, WOODRUFF M, LETTERI J, AGARWAL V, KROL G, HELLER A: Pharmacokinetics and tolerability of the new quinolone Bay 12–8039: 10 days treatment with 400 mg daily. J. Clin. Microbic)]. Infect. (1997) 3 (Suppl. 2):P387, 87.
   Google Scholar
• STASS HH, SCHUHLY U, WINGENDER W: Pharmacoki-netics, safety and tolerability of 600 mg Bay 12–8039 administered once daily over 10 days. J. Clin. Microbic)]. Infect. (1997) 3\(Suppl. 2) P387:87.
   Google Scholar
• STASS H, BRUNNER M, EICHLER HG, MOLLER J-G, MULLER M: Comparison of skin blister fluid and interstital tis-sue kinetics of Bay 12–8039 in healthy volunteers using microdialysis. Abstracts of the 38th ICAAC. San Diego (1998) Al2:4.
   Google Scholar
• WISE R, ANDREWS JM, HARTMAN G: The pharmacoki-netics and penetration of moxifloxacin into a cantharidin-induced inflammatory exudate following oral and iv administration. Abstracts of the 38th ICAAC. San Diego (1998) A27:8.
   Google Scholar
• ANDREWS J, HONEYBOURNE D, JEVONS G, WISE R: Penetration of Bay 12–8039 into bronchial mucosa, epithelial lining. Abstracts of the 38th ICAAC. San Diego (1998) A29:9.
   Google Scholar
• MULLER FO, HUNDT HKL, MUIR AR et al.: Study to inves-tigate the influence of 400 mg Bay 12–8039 given once daily to healthy volunteers on PK and PD of warfarin. Abstracts of the 38th ICAAC. San Diego (1990) A13:4.
   Google Scholar